HOLON, Israel, Feb. 14, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019, before the U.S. financial markets open. Management will host a live webcast to review the results and provide a corporate update at 8:30 AM ET.
To access the live conference call by telephone, please dial 1-888-407-2553 from the U.S., or +972-3-918-0610 internationally. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.
About Compugen Compugen is a clinical-stage, therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel with R&D facilities in both Israel and South San Francisco, CA. Compugen's ordinary shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.
Company contact: Elana HolzmanDirector, Investor Relations and Corporate CommunicationsCompugen Ltd.Email: [email protected] Tel: +972(3)765-8124
Investor Relations contact:Burns McClellan, Inc.Jill SteierEmail: [email protected] Tel: 212-213-0006
Advertisement
To access the live conference call by telephone, please dial 1-888-407-2553 from the U.S., or +972-3-918-0610 internationally. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.
Advertisement
About Compugen Compugen is a clinical-stage, therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel with R&D facilities in both Israel and South San Francisco, CA. Compugen's ordinary shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.
Company contact: Elana HolzmanDirector, Investor Relations and Corporate CommunicationsCompugen Ltd.Email: [email protected] Tel: +972(3)765-8124
Investor Relations contact:Burns McClellan, Inc.Jill SteierEmail: [email protected] Tel: 212-213-0006
View original content:http://www.prnewswire.com/news-releases/compugen-fourth-quarter-and-full-year-2018-conference-call-scheduled-for-tuesday-february-26-2019-at-830-am-et-300795769.html
SOURCE Compugen Ltd.
